Etravirine(eh tra vye’ rin)
IntelenceDNC
PREGNANCY CATEGORY B
Drug Classes
Antiviral
Non-nucleoside reverse transcriptase inhibitor
Therapeutic Actions
Binds directly to reverse transcriptase and blocks both RNA and DNA dependent polymerase activity leading to inability for viral replication, a decrease in viral load and subsequent increase, increases number of healthy CD4+ cells; does not inhibit human DNA polymerase.
Indications
In combination with other antiretroviral drugs, for treatment of HIV-1 infection in treatment-experienced patients 6 yr and older who have evidence of viral replication and HIV-1 strains resistant to non-nucleotide reverse transcriptase inhibitors and other antiretroviral drugs
Contraindications and Cautions
No known contraindications.
Use cautiously with pregnancy. Women are advised not to breast-feed while taking drug.
Available Forms
TabletsDNC—25, 100, 200 mg
Dosages
Adults
200 mg PO bid following a meal.
Pediatric patients 6 to younger than 18 yr
16 to less than 20 kg: 100 mg PO bid.
20 to less than 25 kg: 125 mg PO bid.
25 to less than 30 kg: 150 mg PO bid.
30 kg or more: 200 mg PO bid.
Pharmacokinetics
|
Metabolism: Hepatic: T1/2: 21–61 hr
Distribution: May cross placenta, may enter breast milk
Excretion: Feces and urine
Adverse Effects
CNS: Headache, peripheral neuropathy, vertigo, blurred vision, insomnia, anxiety, paresthesias
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
